Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: SkyQuest | PRODUCT CODE: 1345203

Cover Image

PUBLISHER: SkyQuest | PRODUCT CODE: 1345203

Global Mycoplasma Testing Market Size, Share, Growth Analysis, By Application(Cell Line Testing, Virus Testing), By End-Use(Academic Research Institutes, Cell Banks) - Industry Forecast 2023-2030

PUBLISHED:
PAGES: 157 Pages
DELIVERY TIME: 3-5 business days
SELECT AN OPTION
Single User License
USD 5300
Multiple User License
USD 6200
Enterprise License
USD 7100

Add to Cart

Mycoplasma Testing Market size was valued at USD 262.2 Million in 2021 and is poised to grow from USD 298.91 Million in 2022 to USD 852.66 Million by 2030, at a CAGR of 14% during the forecast period (2023-2030).The primary aim of the mycoplasma testing market is to provide reliable, accurate, and efficient tools and services for detecting and preventing Mycoplasma contamination in diverse settings. This market encompasses a range of products, including kits, reagents, instruments, and software, as well as laboratory services such as testing, validation, and consulting. It serves various industries, including biotechnology, pharmaceuticals, academic research, and clinical diagnostics.

Several factors drive the growth of the mycoplasma testing market. These include the increasing demand for biopharmaceuticals and cell-based therapies, greater awareness of the risks and consequences of mycoplasma contamination, and advancements in testing technologies and platforms. Additionally, stricter regulatory requirements and guidelines for mycoplasma testing have led to a demand for more robust and efficient solutions.However, the mycoplasma testing market faces challenges and constraints. These include the high cost of testing products and services, lack of standardization and harmonization of testing methods, and limited availability of skilled personnel and infrastructure for mycoplasma testing. Addressing issues related to false-positive and false-negative results, cross-reactivity with other contaminants, and the potential genetic variability and adaptation of mycoplasma strains are also crucial for the market's success.

Despite these challenges, the mycoplasma testing market presents various opportunities for growth and expansion. These include developing new testing technologies and platforms, exploring new geographical markets and industries, and integrating mycoplasma testing with other quality control and assurance systems. Leveraging digitization and automation trends in laboratory workflows and data management can also enhance the efficiency and accuracy of mycoplasma testing.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Mycoplasma Testing Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report:

The global mycoplasma testing market is segmented on the application, end-use and region. By application, the market is segmented into cell line testing, virus testing, end of production cells testing, others. By end-use, the market is segmented into academic research institutes, cell banks, contract research organizations, pharmaceutical & biotechnology companies, and others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver:

The Mycoplasma testing market is experiencing growth due to the increasing demand for biopharmaceuticals and cell-based therapies. To ensure the safety and effectiveness of these products and therapies, it is essential to use high-quality cells that are free from Mycoplasma contamination. Therefore, Mycoplasma testing plays a crucial role in verifying the absence of this contamination and maintaining the integrity of biopharmaceuticals and cell-based treatments.

Restraint:

The expense associated with mycoplasma testing products and services can present a considerable obstacle for numerous customers, particularly in emerging markets or low-resource settings. The cost of mycoplasma testing can fluctuate based on factors such as the test type, sample complexity, and the sensitivity and specificity of the chosen method. Advanced testing approaches like PCR-based assays or high-throughput sequencing can be particularly costly, rendering them inaccessible to certain customers. As a result, affordability remains a critical challenge for widespread adoption of mycoplasma testing, and efforts to develop more cost-effective solutions may enhance accessibility and benefit a broader range of users.

Market Trends:

The Mycoplasma testing market is experiencing advancements in testing technologies and platforms, including PCR-based assays, nucleic acid sequencing, and flow cytometry. These cutting-edge methods offer improved sensitivity, specificity, and efficiency compared to traditional culture-based techniques.

Another notable trend in the market is the integration of Mycoplasma testing with other quality control and assurance systems. This includes combining Mycoplasma testing with microbial identification, endotoxin testing, and bioburden testing. The integration of these complementary systems allows customers to optimize their workflows, leading to reduced turnaround time and testing costs while maintaining high levels of accuracy and reliability. This integration is becoming more prevalent as customers seek more comprehensive and streamlined solutions for ensuring product safety and quality in various industries.

Product Code: SQMIG35I2167

Table of Contents

  • Executive Summary
    • Market Overview
    • Wheel of Fortune
  • Research Methodology
    • Information Procurement
    • Secondary & Primary Data Sources
    • Market Size Estimation
    • Market Assumptions & Limitations
  • Parent Market Analysis
    • Market Overview
    • Market Size
    • Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
  • Key Market Insights
    • Technology Analysis
    • Pricing Analysis
    • Supply Chain Analysis
    • Value Chain Analysis
    • Ecosystem of the Market
    • IP Analysis
    • Trade Analysis
    • Startup Analysis
    • Raw Material Analysis
    • Innovation Matrix
    • Pipeline Product Analysis
    • Macroeconomic Indicators
    • Top Investment Analysis
    • Key Success Factor
    • Degree of Competition
  • Market Dynamics & Outlook
    • Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
    • Regulatory Landscape
    • Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
    • Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact
  • Global Mycoplasma Testing Market by Application
    • Market Overview
    • Cell Line Testing
    • Virus Testing
    • End of Production Cells Testing
    • and Others
  • Global Mycoplasma Testing Market by End-Use
    • Market Overview
    • Academic Research Institutes
    • Cell Banks
    • Contract Research Organizations
    • Pharmaceutical & Biotechnology Companies
    • and Others
  • Global Mycoplasma Testing Market Size by Region
    • Market Overview
    • North America
  • USA
  • Canada
    • Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
    • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
    • Latin America
  • Brazil
  • Rest of Latin America
    • Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA
  • Competitive Landscape
    • Top 5 Player Comparison
    • Market Positioning of Key Players, 2021
    • Strategies Adopted by Key Market Players
    • Top Winning Strategies
  • By Development
  • By Company
  • By Year
    • Recent Activities in the Market
    • Key Companies Market Share (%), 2021
  • Key Company Profiles
    • Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Thermo Fisher Scientific Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Lonza Group Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Sartorius AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • PromoCell GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • American Type Culture Collection (ATCC) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Agilent Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Bionique Testing Laboratories, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Biological Industries Israel Beit Haemek Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Charles River Laboratories International, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Creative Bioarray (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • InvivoGen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Minerva Biolabs GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Biological Industries US, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Norgen Biotek Corp. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Novacyt Group (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Mycoplasma Experience (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Genscript Biotech Corporation (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • GeneCopoeia, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
    • Jena Bioscience GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!